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Abstract Reactive blue 2 (RB-2) had been characterized as
a relatively potent ectonucleoside triphosphate diphospho-
hydrolase (E-NTPDase) inhibitor with some selectivity for
NTPDase3. In search for the pharmacophore and to analyze
structure-activity relationships we synthesized a series of
truncated derivativesand analogs of RB-2,including 1-amino-
2-sulfo-4-ar(alk)ylaminoanthraquinones, 1-amino-2-methyl-4-
arylaminoanthraquinones, 1-amino-4-bromoanthraquinone
2-sulfonic acid esters and sulfonamides, and bis-(1-amino-
4-bromoanthraquinone) sulfonamides, and investigated them
in preparations of rat NTPDase1, 2, and 3 using a capillary
electrophoresis assay. Several 1-amino-2-sulfo-4-ar(alk)ylami-
noanthraquinone derivatives inhibited E-NTPDases in a
concentration-dependent manner. The 2-sulfonate group
was found to be required for inhibitory activity, since 2-
methyl-substituted derivatives were inactive. 1-Amino-2-sulfo-
4-p-chloroanilinoanthraquinone (18) was identified as a
nonselective competitive blocker of NTPDases1, 2, and 3
(Ki 16–18 μM), while 1-amino-2-sulfo-4-(2-naphthylamino)
anthraquinone (21) was a potent inhibitor with preference for
NTPDase1 (Ki 0.328 μM )a n dN T P D a s e 3( K i 2.22 μM). Its
isomer, 1-amino-2-sulfo-4-(1-naphthylamino)anthraquinone
(20), was a potent and selective inhibitor of rat NTPDase3
(Ki 1.5 μM).
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Abbreviations
ARL 67156 N
6-diethyl-β,γ-dibromomethylene-ATP
CE capillary electrophoresis
DMSO dimethyl sulfoxide
EI electron impact
ESI electrospray ionization
HEPES N-[2-hydroxyethyl]piperazine-N′-
2-ethanesulfonic acid
HPLC high-performance liquid chromatography
HRMS high-resolution mass spectrometry
NMR nuclear magnetic resonance
(E)-NTPDase (ecto)-nucleoside 5′-triphosphate
diphosphohydrolase
PPADS pyridoxal phosphate-6-azophenyl-2′,
4′-disulfonic acid
RB-2 reactive blue 2
SAR(s) structure-activity relationship(s)
Introduction
Extracellular nucleotides such as ATP, adenosine diphos-
phate (ADP), uridine triphosphate (UTP), and uridine
diphosphate (UDP) act as extracellular signaling molecules
in virtually all tissues and organs [1]. Especially ATP is
involved in a variety of physiological and pathological
functions in the body, e.g., as a neurotransmitter and neuro-
modulator in the central and peripheral nervous system, as a
key messenger in nociception, as a tumor-inhibiting agent, in
the control of secretion from a variety of endocrine glands, in
the modulation of platelet aggregation by ADP, in chloride
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Frankfurt am Main, Germanytransport in the airway epithelia, in renal function, in bone
and cartilage disease, and as a proinflammatory agent in the
immune system [2, 3]. Extracellular nucleotides are efficient-
ly inactivated by surface-located enzymes which sequentially
hydrolyze the phosphate groups eventually resulting in the
formation of the respective nucleoside and inorganic phos-
phate [4]. Nucleoside 5′-triphosphates and 5′-diphosphates
may be hydrolyzed by members of the E-NTPDase (ecto-
nucleoside triphosphate diphosphohydrolase) family, the E-
NPP (ectonucleotide pyrophosphatase/phosphodiesterase)
family, and by alkaline phosphatases. Nucleoside 5′-mono-
phosphates are subject to hydrolysis by ecto-5′-nucleotidase
and also by alkaline phosphatases [5]. Members of the various
ectonucleotidase families reveal overlapping substrate speci-
ficity and tissue distribution whose functional significance
needs to be further elucidated [4].
E-NTPDases comprise eight members, four of which have
two plasma membrane-spanning domains with an active site
facing the extracellular milieu [4–6], namely, NTPDase1
(CD39), NTPDase2 (CD39L1), NTPDase3 (CD39L3), and
NTPDase8 [7, 8]. In contrast, NTPDase4, 5, 6, and 7 are
intracellular membranes proteins. Even though NTPDases5
and 6 may be present at the surface of the plasma membrane
and secreted as soluble enzymes following a proteolytic
cleavage, their high Km values and low specific activities [9]
make it unlikely that these enzymes regulate P2 receptor
signaling. NTPDases share five highly conserved sequence
domains (apyrase conserved regions) that are presumably of
major relevance for their catalytic activity [10]. They contain
the actin-HSP 70-hexokinase β-a n dγ-phosphate binding
motif [11, 12].
Members of the E-NTPDase family can hydrolyze nucle-
oside 5′-triphosphates and nucleoside 5′-diphosphates albeit
with varying preference for the individual type of nucleotide
[10, 11]. NTPDase1 (CD39, ectoapyrase, ecto-ATP diphos-
phohydrolase) hydrolyzes ATP and ADP at a molecular ratio
of about 1:0.5 to 1:0.9 [13]. In contrast, NTPDase2 has a
strong preference for ATP with molecular ratios of ATP:ADP
of 1:0.03 or less. NTPDase3 is a functional intermediate and
reveals a molecular ratio of ATP:ADP of approximately 1:0.3.
The activity of all three types of ectonucleotidases depends on
millimolar concentrations of divalent cations such as Ca
2+ or
Mg
2+ [11, 13, 14]. The enzymes hydrolyze not only ATP or
ADP but have broad substrate specificity towards purine and
pyrimidine nucleotides.
The analysis of nucleotide release requires the availability
of inhibitors of ectonucleotidases that should ideally have no
effect on P2 receptor activation [6]. It has been demonstrated
that stable analogs of ATP can elicit tissue contractions up to
100 times more effectively than ATP. This suggests that the
effects of exogenously applied ATP on P2 receptors are
limited by its enzymatic degradation. Inhibitors of ectonu-
cleotidases could thus serve as drugs that increase the life-
time of extracellular ATP (or ADP, UTP, or UDP) in situ.
They could act in a site- and event-specific manner since
they would only have an effect when nucleotides are present.
NTPDase1isthe major physiological E-NTPDasemember
showing a nearly ubiquitous tissue distribution. It is constitu-
tively expressed in microvascular endothelium and certain
immune cells and plays an important role in thromboregula-
tion and immune function [15]. The distribution of
NTPDase2 appears to be more restricted. NTPDase2 has
been detected on blood vessels [16], cultured brain astrocytes
[17], and on certain neuronal progenitor [18] and cancer cells
[19, 20]. In contrast, NTPDase3 is expressed in the brain
exclusively in neurons, with a predominantly axonal local-
ization. Its colocalization with hypocretin-1/orexin-A indi-
cates that it may be involved in the modulation of feeding,
the sleep-wake cycle, or other behavioral components [21].
NTPDase3 has also been reported to be involved in auditory
neurotransmission since it is highly expressed in the cochlea
[22].
Potent and selective inhibitors for the individual
NTPDase isoenzymes are required as pharmacological tools
to investigate the (patho)physiological roles of NTPDases.
Furthermore, such compounds are required to study their
potential as novel drugs, e.g., for the treatment of cancer, as
immunomodulatory agents, and for the treatment of cardio-
vascular or central nervous system disorders. So far only few
classes of NTPDase inhibitors have been described [23]
(Fig. 1).
These include nucleotide derivatives and analogs, mainly
derived from ATP. Until recently, the only compound that
has been shown to effectively inhibit the hydrolysis of ATP
in a variety of tissues (albeit with moderate potency) with-
out significantly acting on P2 receptors was the structural
analog of ATP, ARL 67156 (1, FPL 67156) (N
6-diethyl-β,
γ-dibromomethylene-ATP) [24–26]. However, ARL 67156
was recently found to be nearly inactive at rat, mouse, and
human NTPDase2 [27, 28]. Although 1 is stable versus
ecto-alkaline phosphatases and E-NTPDases, it might be
hydrolyzed by E-NPPs, which directly attack the oxygen
bridge between the α- and β-phosphorus atom of ATP
and related compounds. However, Sévigny and colleagues
showed that human NPP1 and NPP3 were unable to
hydrolyze ARL 67156 [28]. 8-Thioether-ATP derivatives,
found inactive at P2Y and P2X receptors, and stable to
NTPDase hydrolysis, have also been described as NTPDase
inhibitors. 8-Butylthioadenosine-5′-triphosphate (compound
2) acts as a competitive inhibitor of ATP with an estimated
Ki value of 10 μM at NTPDase from bovine spleen [29].
Although the compound appears to be stable against
NTPDases, it is likely to be hydrolyzed by the ubiquitously
present ectoalkaline phosphatases which accept a very broad
variety of substrates. Very recently, we have developed
metabolically stable, uncharged nucleotide mimetics derived
92 Purinergic Signalling (2009) 5:91–106from uridine 5′-carboxylate and identified PSB-6426 (3)a sa
selective inhibitor of human NTPDase2 [30].
Besidesinhibitors derived from nucleotides, non-nucleotide
NTPDase inhibitors have been described. These include
suramin (4) and related compounds [13, 31–33], sulfonate
dyes such as reactive blue 2 (RB-2, 5)[ 34–37], and PPADS
(6, pyridoxal phosphate-6-azophenyl-2′,4′-disulfonic acid)
[13, 38, 39], which can all attenuate the hydrolysis of ATP.
However, all of these compounds are nonselective, as they
are also potent antagonists at P2 receptors. We recently
identified a novel class of NTPDase inhibitors, the poly-
oxometalates (POMs), which are inorganic anionic metal
complexes, e.g., POM-4 (7)[ 40]. These compounds have
turned out to be useful pharmacological tools [41–43].
However, they have high molecular weights, bear several
negative charges, and are not drug-like molecules.
The present study was aimed at identifying the pharma-
cophore of RB-2 for inhibiting NTPDases and at investi-
gating the structure-activity relationships of truncated RB-2
derivatives. Since RB-2 shows some selectivity for rat
NTPDase3 (Ki 1.10 μM, approximately 20-fold selectivity
vs NTPDase1 and 2) [27, 44], we expected that this strategy
might lead to the identification of an NTPDase3-selective
inhibitor.
Results and discussion
Syntheses
The 1-amino-4-anilino-2-sulfoanthraquinone derivatives
11–19 were synthesized as recently described by combina-
torial parallel synthesis using the Ullmann coupling
reaction [45]. The new compounds 20–22 were obtained
by two different methods. The 1-naphthyl (20) and the 3,
4-dimethoxyphenyl derivative (22) were synthesized by
the classic Ullmann reaction from bromaminic acid (8) and
1-naphthylamine, or 3,4-dimethoxyphenethylamine, respec-
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Fig. 1 Structures of NTPDase inhibitors
Purinergic Signalling (2009) 5:91–106 93tively, in water in the presence of potassium carbonate and
copper sulfate at 100–105°C (see Fig. 2). The 2-naphthyl
derivative (21) was obtained by a new microwave-catalyzed
Ullmann reaction in phosphate buffer using elemental
copper as a catalyst [46] within only 5 min reaction time
(Fig. 2). The 1-amino-2-methyl-4-arylaminoanthraquinone
derivatives 23–26 were obtained by solvent-free reaction of
1-amino-4-bromo-2-methylanthraquinone (9) with the ap-
propriate arylamine derivative in the presence of copper
acetate and potassium acetate at 110°C for 5–24 h accord-
ing to a procedure described by Harris et al. [47] (see
Fig. 2).
Anthraquinone sulfonic acid esters 27–30 and sulfona-
mides (31–33) were obtained by chlorination of broma-
minic acid (8) with phosphorus pentachloride in
phosphorus oxychloride to yield the sulfonic acid chloride
10 as a reactive intermediate, which was subsequently
treated with the appropriate alcohol or phenol, or ar(alkyl)
amine under basic conditions (Fig. 3). When p-ethoxy- or
o-methoxy-substituted aniline was used for the condensa-
tion with 10, the desired simple sulfonamide derivatives
were not obtained. Mass spectral and nuclear magnetic
resonance (NMR) analysis revealed that bissulfonamides 34
and 35 had formed instead, although the anilines had been
present in the reaction mixtures in excess. The explanation
may be an increased nucleophilicity of the aniline nitrogen
atom due to the positive mesomeric effects of the
substituents (o-methoxy, p-ethoxy).
Solubility and stability of selected anthraquinone
derivatives
It was observed that some anthraquinone sulfonic acid
sodium salts, which were initially well soluble in water,
formed precipitates during the testing. One explanation may
be that the high salt concentrations in the buffer solutions,
e.g., the presence of calcium ions, which may form hardly
soluble calcium sulfonates, reduced their solubility. Howev-
er, precipitation might also be due to another chemical
reaction. Therefore, selected 1-amino-4-phenylamino-2-
sulfoanthraquinone derivatives (12, 15, 17, 18) bearing
different substituents on the phenyl ring (o-methyl, o, p-
dimethyl, o-ethoxy, and p-chloro residues) were investigated
for their stability under the test conditions. Aqueous solutions
(10 mM) were prepared and diluted with the N-[2-hydrox-
yethyl]piperazine-N′-2-ethanesulfonic acid (HEPES) buffer
that was used in the assays, to obtain a compound concen-
tration of 3 mM. After a short period of time after dilution,
compound 18 precipitated, while the other compounds stayed
in solution. After 15 h at room temperature, compound 17
also started to precipitate, while 12 precipitated after 48 h and
15 after about 1 week. The precipitated compounds were
collected by filtration, dried, and NMR spectra were recorded
showing that the precipitated compounds were structurally
identical to the original anthraquinone derivatives. This result
indicates that the compounds were not degraded, but
precipitated upon dilution with buffer solutions due to the
lower solubility in the presence of high salt concentrations
probably due to the formation of poorly soluble salts of the
anthraquinone sulfonic acids with cations in the buffer
(HEPES and/or calcium). Since precipitation in most cases
only occurred after several hours, testing of high concen-
trations was always performed with freshly prepared solutions.
Investigation of anthraquinone derivatives as potential
inhibitors of nucleoside triphosphate diphosphohydrolases
by capillary electrophoresis
Inhibition of rat NTPDases1, 2, and 3 was performed
essentially as previously described using a capillary electro-
phoresis (CE) method [27]. Membrane preparations derived
from transfected cells containing rat NTPDase1, NTPDase2,
or NTPDase3 were employed. A fixed substrate concentra-
tion of 400 μM was used. Test compounds were initially
screened at a concentration of 1 mM. For compounds which
showed about 50% inhibition or more, IC50 values were
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94 Purinergic Signalling (2009) 5:91–106determined with six to eight different concentrations of
inhibitor spanning about three orders of magnitude. After
stopping the reaction by heating, an aliquot was subjected to
CE analysis with UV detection at 210 nm. Under the applied
conditions less than 10% of substrate was converted by the
enzymes. Ki values were calculated from IC50 values as
previously described assuming a competitive inhibition
mechanism [27].
Structure-activity relationships
Even though the investigated 1-amino-2-sulfo-4-ar(alk)-
ylaminoanthraquinone derivatives exhibited only a partial
structure of RB-2 and were much smaller than the parent
compound, many of them were similarly or even more
active as NTPDase inhibitors (Table 1). For example, com-
pound 18 bearing a p-chlorophenylamino residue was a
potent, nonselective NTPDase inhibitor (Ki 16–18 μM).
While NTPDase2 and 3 were quite tolerant with regard to
the substituent in the 4-position accepting a large variety
of differentially substituted arylamino residues and even
a 3,4-dimethoxyphenethylamino residue, structure-activity
relationships (SARs) of NTPDase1 were more restricted:
phenylamino (11), m-methylphenylamino (13), and partic-
ularly o,p-dimethylphenylamino (15) and p-chlorophenyla-
mino (18) were best tolerated, while monosubstitution in
the ortho-position of the phenylamino residue (12, 16, 17)
or replacement of the phenyl ring by 1-naphthyl (20)o ra
3,4-dimethoxyphenethyl residue (22) were not well tolerat-
ed by rat NTPDase1. On the other hand, a 2-naphthyl ring
was very well tolerated by NTPDase1: compound 21 was
the most potent NTPDase1 inhibitor of the present series
with a Ki value of 0.328 μM; it was less potent at
NTPDase3 (Ki 2.22 μM) and much less potent at
NTPDase2 (19.1 μM). Small p-substituents on the phenyl
ring (p-chloro, p-methyl) were well accepted by NTPDase1,
while an acetylamino residue in the p-position was
detrimental. Compound 20 was the most potent and
selective inhibitor of rat NTPDase3 and not inhibitory to
rat NTPDase1 and 2 even at high, millimolar concentra-
tions. Rat NTPDase3 appears to have a lipophilic pocket
which can accommodate a 1-naphthylamino residue in the
4-position. Concentration-inhibition curves of the most
potent nonselective NTPDase inhibitor 18 (PSB-069) at
the three investigated NTPDases and of the NTPDase3-
selective inhibitor 20 (PSB-06126) are shown in Fig. 4.
An unsubstituted sulfonate group in the 2-position of the
anthraquinone scaffold was essential for inhibitory activity.
Replacement of the sulfonate by a methyl group (23–26)
abolished activity. Bromaminic acid derivatives, in which
the sulfonic acid group was converted to sulfonic acid
esters (27–30) or sulfonamides (31–33), were also totally
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Purinergic Signalling (2009) 5:91–106 95Table 1 Inhibitory potencies of anthraquinone derivatives at rat NTPDase1, 2, and 3 determined by capillary electrophoresis
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Inhibitor R Ki (μM)±SEM (or percent inhibition at 1 mM)
NTPDase1 NTPDase2 NTPDase3
1 ARL 67156 [27] 27.0±0.0 (50%) 112±0
5 Reactive blue 2 (RB-2) [27] 20.0±0.0 24.20±0.06 1.10±0.03
1-Amino-4-aryl(alkyl)amino-2-sulfo-anthraquinones
11 Phenyl 49.1±5.1 35.8±6.1 14.3±1.5
12 2-Methylphenyl (25%) 25.7±5.1 23.0±2.5
13 3-Methylphenyl 51.5±0.4 12.8±0.9 19.1±6.0
14 2,3-Dimethylphenyl (67%)
b 22.7±3.4 38.5±5.0
15 2,4-Dimethylphenyl 18.0±3.5 15.6±2.5 41.8±5.5
16 2-Methoxyphenyl (57%) 53.8±5.7 17.6±6.6
17 2-Ethoxyphenyl (17%) 40.8±11.1 58.0±12.7
18 4-Chlorophenyl 15.7±3.4 18.0±2.0 16.4±1.6
19 4-Acetylaminophenyl (15%) 486±18 343±63
20 1-Naphthyl (0%) (0%) 1.5±0.1
21 2-Naphthyl 0.328±0.110 19.1±1.6 2.22±1.03
22 3,4-Dimethoxy-phenethyl 173±6 54.1±6.8 23.4±0.4
1-Amino-4-arylamino-2-methyl-anthraquinones
23 Phenyl (0%) (0%) (0%)
24 3-Methylphenyl (0%) (0%) (0%)
25 4-Methylphenyl (0%) (0%) (0%)
26 1-Naphthyl (0%) (0%) (0%)
1-Amino-4-bromo-anthraquinone 2-sulfonates or 2-sulfonamides
27 Methoxy (0%) (0%) (0%)
28 2-Nitrophenoxy (0%) (0%) (0%)
29 3-Nitrophenoxy (0%) (0%) (0%)
30 4-Nitrophenoxy (0%) (0%) (0%)
31 Phenylamino (0%) (0%) (0%)
32 Benzylamino (0%) (0%) (0%)
33 Phenethylamino (0%) (0%) (0%)
96 Purinergic Signalling (2009) 5:91–106inactive. Thus, a negative charge (a free sulfonate group)
appeared to be required for NTPDase inhibition. This is in
agreement with previous studies on sulfonate dyes and
related compounds, which showed that sulfonate groups in
certain positions of the molecules were important for
ectonucleotidase inhibitory activity [23, 34].
In order to investigate the inhibition mechanism of this
class of NTPDase inhibitors, kinetics of NTPDase3 were
exemplarily determined in the absence and in the presence of
compound 18 (10, 20, and 30 μM). While the Vmax value
was not affected by the inhibitor, the Km value increased
with increasing concentration of inhibitor indicating a
competitive mechanism of inhibition (for Lineweaver-Burk
plot see Fig. 5).
The present study is the first one to systematically
investigate the SARs of anthraquinone derivatives derived
from RB-2 at defined NTPDase isoenzymes. We could
confirm previous findings by Tuluc et al. [37] that anthra-
quinone derivatives with only one substituted phenyl ring at
the 4-amino group, which are much smaller than RB-2, can
exhibit ectonucleotidase inhibitory activity. However, com-
pound 11 (also known as acid blue 25) was inactive (at
100 μM) in their study investigating ATP degradation in rat
vas deferens tissue [37]. Like RB-2, its truncated derivatives
Table 1 (continued)
Inhibitor R Ki (μM)±SEM (or percent inhibition at 1 mM)
NTPDase1 NTPDase2 NTPDase3
Bis-(1-amino-4-bromo-anthraquinone) sulfonamides
34 4′-Ethoxy (0%) (0%) (0%)
35 2′-Methoxy (0%) (0%) (0%)
aThe results are means±SEM of three separate experiments each run in duplicate
bCurve could not be determined: inhibition was not concentration dependent; there was no inhibition at 100 μM
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Fig. 4 Concentration-inhibition
curves of selected anthraquinone
derivatives. Top: curves of the
nonselective NTPDase inhibitor
18 at NTPDase1, 2, and 3.
Bottom: curve of the NTPDase3
inhibitor 20
Purinergic Signalling (2009) 5:91–106 97also interact with P2 receptors [37, 45, 48]. However, the
SARs are clearly different. For example, 16 (PSB-716) was
shown to be a potent P2Y2 antagonist (IC50 ca. 9 μM) [45],
but it is only a weak NTPDase1 inhibitor. Compound 19 was
also a potent inhibitor at P2Y2 (IC50 6–12 μM) [45], but
nearly inactive at all three NTPDases tested.
Conclusions
We have investigated 25 anthraquinone derivatives related to
RB-2 for their potency at inhibiting rat NTPDases1, 2, and 3
in order to obtain initial information about their structure-
activity relationships. While 11 of the compounds had
previously been reported, 14 compounds are new and their
syntheses and physicochemical characterization are described
for the first time. Certain 1-amino-2-sulfo-4-arylaminoanthra-
quinones were identifiedaspotentNTPDaseinhibitors. While
the 4-chlorophenylamino derivative 18 was a nonselective
inhibitor (Ki 16–18 μM), the 4-(1-naphthylamino) derivative
20 was very potent and selective for rat NTPDase3 versus rat
NTPDase1 and 2. In contrast, its 2-naphthylamino isomer 21
was a very potent NTPDase1 inhibitor (Ki 0.328 μM). For
future studies it would be of interest to investigate potential
species differences of these and other NTPDase inhibitors.
Furthermore, it will be important to investigate the potency
of some of these compounds at other ectonucleotidases,
including ecto-5′-nucleotidase, nucleotide pyrophosphatases/
phosphodiesterases (NPPs), and alkaline phosphatases, and
to determine their profile at the various P2Y and P2X
receptor subtypes, in order to be able to fully assess their
usefulness as pharmacological tools. The compounds de-
scribed will be good starting points for further optimization.
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Appendix
Experimental section
Reagents and chemicals
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES),
ATP, MgCl2·6H2O, and tris(hydroxymethyl)aminomethane
(Trizma Base), penicillin and streptomycin were purchased
from Sigma-Aldrich (Taufkirchen, Germany). Culture medium
was obtained from Invitrogen (Karlsruhe, Germany). Leupep-
tin, pepstatin A, chymostatin, and antipain were received from
Calbiochem (Schwalbach, Germany).
Bromaminic acid (8) and 1-amino-4-bromo-2-methylan-
thraquinone (9) were obtained from Sigma-Aldrich (Tauf-
kirchen, Germany). Aniline derivatives were a gift from
Bayer AG (through Fonds der Chemischen Industrie).
Liquid aniline derivatives were purified by distillation
before use in case they showed a dark brown color.
Solvents were dried according to standard methods when
required. All other chemicals were obtained from standard
commercial sources or prepared as described below.
Anthraquinone derivatives 11–19 were prepared as recently
published [45, 46].
Instruments
NMR spectra were recorded on a Bruker Avance 500
spectrometer. Electron impact mass spectra (EI-MS) were
obtained on an MS 50 instrument of the company A.E.I., or
a MAT 95 XL instrument of Thermoquest. Polar com-
pounds were analyzed by electrospray ionization using the
API 2000 LC-MS instrument from Applied Biosystems.
Elemental analyses were performed with a VarioEL
instrument of Elementar Analysensysteme GmbH. Melting
points were determined on a Gallenkamp apparatus, or a
B530 or a B-545 apparatus from Büchi. Melting points of
sodium sulfonates were usually not determined because
they are >300°C. Reactions were monitored by thin-layer
chromatography (TLC) using silica gel plates F254 and/or
RP silica gel plates F254. For microwave reactions a CEM
Focused™ Microwave Synthesis type Discover apparatus
was used. A freeze dryer (CHRIST ALPHA 1–4 LSC) was
used for lyophilization.
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Fig. 5 Lineweaver-Burk plot for rat NTPDase3 kinetics in the
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Sodium 1-amino-4-(1-naphthylamino)-9,10-dioxo-9,
10-dihydroanthracene 2-sulfonate (20)
Bromaminic acid sodium salt (0.500 g, 1.25 mmol), Na2CO3
(0.175 g), and CuSO4 (0.030 g) were dissolved in 10 ml of
water. Then 2 g (14 mmol) of 1-aminonaphthalene was
added and the reaction mixture was stirred for 16 h at 105°C.
After completion of the reaction the mixture was cooled for
4 h at 4°C, and the formed precipitate was filtered off. The
precipitate was washed with 10 ml of water and subsequent-
ly with 200 ml of dichloromethane until the filtrate became
colorless. The residue was dried under vacuum. Yield:
0.281 g (49%); mp>300°C.
1H-NMR [dimethyl sulfoxide
(DMSO)-d6, 500 MHz, 303 K]: δ (ppm)=7.49 (br, 1H,
NH2); 7.50 (d, 1H,
3J=7.3 Hz, naphthalene); 7.58–7.63 (m,
3H, naphthalene); 7.80 (s, 1H, C3H); 7.84–7.90 (m, 3H,
C6H, C7H, naphthalene); 8.02, 8.08 (m, 2H, naphthalene);
8.32 (m, 2H, C5H, C8H); 10.12 (br, 1H, NH2); 12.51 (s, 1H,
NH).
13C-NMR (DMSO-d6, 125 MHz, 303 K): δ (ppm)=
109.23, 111.46 (C4a, C9a); 121.55, 121.97 (C2′,C 4 ′);
122.92 (C3); 125.76, 126.20 (2C), 126.24, 126.91, 127.12,
128.67, 129.00 (C5, C8, C5′,C 6 ′,C 7 ′,C 8 ′,C 4 a ′,C 8 a ′);
132.94, 133.38, 133.78, 134.40, 134.48, 135.21 (C6, C7,
C8a, C10a, C1′,C 3 ′); 142.58, 143.15, 144.49 (C1, C2, C4);
181.92, 182.95 (C9, C10). FAB m/z (%)=466 (100,
C25H15N2O5SNa); 444 (46, C25H15N2O5S).
Sodium 1-amino-4-(2-naphthylamino)-9,10-dioxo-9,
10-dihydroanthracene 2-sulfonate (21)
The synthesis was performed in analogy to a recently
described procedure [46]. To a 5-ml microwave reaction vial
equipped with a magnetic stirring bar were added broma-
minic acid sodium salt (0.081 g, 0.20 mmol) and 1-amino-
naphthalene (80 mg, 0.40 mmol), followed by a buffer
solution consisting of 4 ml (0.2 M) aq. Na2HPO4 solution
(pH 9.6) and 1 ml (0.12 M) of NaH2PO4 ( p H4 . 2 ) .Ac a t a l y t i c
amount (ca. 0.002–0 . 0 0 3g )o ff i n e l yp o w d e r e de l e m e n t a l
copper was added. The mixture was capped and irradiated in
the microwave oven (100 W) for 5 min at 120°C. Then the
reaction mixture was cooled to room temperature (RT), and
the product was purified using the following procedure. The
contents of the vial were filtered to remove the elemental
copper. Then water (approximately 200 ml) was added to the
filtrate and the aqueous solution was extracted with chloro-
form (200 ml). The extraction procedure was repeated until
the organic layer became colorless (2–3 times). Then the
aqueous layer was reduced by rotary evaporation to a volume
of ca. 10 ml, which was subsequently submitted to flash
column chromatography using RP-18 silica gel and water as
an eluent. The polarity of the eluent was then gradually
decreased by the addition of methanol in the following steps:
20, 40, 60, 80, and 100%. Fractions containing blue product
were collected. The pooled product-containing fractions were
evaporated under reduced pressure to remove the methanol,
and the remaining water was subsequently removed by
lyophilization to yield 21 as blue powder. Yield: 0.046 g
(50%); mp>300°C.
1H-NMR: δ 7.49 (m, 3H, naphthalene);
7.76 (d, 1H, naphthalene); 7.86 (m, 2H, 6-H, 7-H); 7.92 (d,
1H, naphthalene); 8.00 (d, 1H, naphthalene); 8.09 (s, 1H, 3-
H); 8.29 (m, 2H, 5-H, 8-H); 10.12 (br, 2H, 1-NH2); 12.16 (s,
1H, NH).
13C-NMR: δ 109.4, 112.0 (C4a, C9a); 119.3, 123.1
(C2′,C 4 ′); 123.3 (C3); 125.3, 126.1, 126.2, 126.9, 127.3,
127.8, 129.6, 130.5 (C5, C8, C5′,C 6 ′,C 7 ′,C 8 ′,C 4 a ′,C 8 a ′);
133.0, 133.4, 133.7, 134.0, 134.3, 137.1 (C6, C7, C8a,
C10a, C1′,C 3 ′); 140.7, 142.90, 144.6 (C1, C2, C4); 182.0
(C9), 182.8 (C10). LC-MS (m/z): 462 [M-Na+NH4
+]
+,4 4 5
[M-Na]
+, 443 [M-Na]
-. Purity by high-performance liquid
chromatography (HPLC)-UV (254 nm)-electrospray ioniza-
tion (ESI)-MS: 98%.
Sodium 1-amino-4-(3,4-dimethoxyphenethylamino)-9,
10-dioxo-9,10-dihydroanthracene 2-sulfonate (22)
Bromaminic acid sodium salt (1.0 g, 2.5 mmol), Na2CO3
(0.210 g), and CuSO4 (0.070 g) were suspended in 20 ml of
water. Then 3,4-dimethoxyphenethylamine (670 μl,
0.725 g, 4.0 mmol) was added and the reaction mixture
was heated at 60°C. Then another portion of 3,4-dimethox-
yphenethylamine (1 ml, 1.09 g, 6 mmol) was added and the
reaction mixture was stirred for 6 h at 100°C. After the
reaction was completed the mixture was cooled and
neutralized by the addition of diluted aq. HCl solution.
Then 20 ml of water containing 1 ml of saturated aq. NaCl
solution were added. The blue-colored solid material was
filtered off and washed twice with 20 ml of a saturated
NaCl solution, and subsequently three times with 20 ml of
dichloromethane each. The residue was dissolved in 200 ml
of a mixture of hot water:methanol (1:3) and filtered. The
filtrate was evaporated to dryness yielding a blue-violet
product, which was further purified by preparative HPLC in
analogy to a described procedure [45]. Yield: 54%; mp>
300°C.
1H-NMR (DMSO-d6, 303 K, 500 MHz): δ (ppm)=
2.90 (t, 2H,
3J=6.9 Hz, ArCH2); 3.63 (dt,
3JHNCH=5.3 Hz,
3JCH2CH2=6.9 Hz NHCH2); 3.71 (s, 3H, C3′-OCH3 or C4′-
OCH3); 3.77 (s, 3H, C3′-OCH3 or C4′-OCH3); 6.84 (dd, 1H,
3J=8.0 Hz,
4J=1.7 Hz, C6′H); 6.89 (d, 1H,
3J=8.2 Hz, C5′
H); 6.97 (d, 1H,
4J=1.6Hz,C2′H); 7.40 (br, 1H, NH2); 7.77–
7.80 (m, 2H, C6H, C7H); 7.81 (s, 1H, C3H); 8.19–8.26 (m,
2H, C5H, C8H); 10.08 (br, 1H, NH2); 10.76 (t, 1H,
3J=
5.2 Hz, NH).
13C-NMR (DMSO-d6, 303 K, 125 MHz): δ
(ppm)=34.88 (ArCH2); 44.35 (NHCH2); 55.49, 55.68 (C3′-
OCH3,C 4 ′-OCH3); 109.07, 109.29 (C4a, C9a); 112.23,
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(C5, C8); 131.52 (C1′); 132.56, 132.64, 134.05, 134.10 (C6,
C7, C8a, C10a); 143.20, 143.72, 145.06 (C1, C2, C4);
147.57, 148.87 (C3′,C 4 ′); 180.97, 181.74 (C9, C10).
General procedure for the synthesis of 4-substituted
1-amino-2-methylanthraquinone derivatives (23–26)
1-Amino-4-bromo-2-methylanthraquinone (9), potassium ac-
etate, and copper(I) acetate were put together into a mortar
and pestled until a finely ground powder was obtained. The
mixture was then transferred to a round-bottom flask and the
appropriate aniline, or aminonaphthalene derivative, respec-
tively, was added. The mixture was then heated at 100°C
under an argon atmosphere upon stirring for 5–24 h. After
cooling, ethanol (5–10 ml) was added and the solid residue
was collected by filtration, washed with ethanol, 2 N
aqueous HCl solution, and water (15 ml each) and finally
recrystallized from pyridine (if necessary).
1-Amino-2-methyl-4-phenylaminoanthraquinone (23)
The compound was synthesized from 500 mg (1.6 mmol)
of 9 and 2 ml (2.04 g, 22 mmol) of aniline in the presence
of 350 mg (3.6 mmol) of potassium acetate and 30 mg
(0.16 mmol) of copper(I) acetate. Reaction time: 5 h.
Yield: 331 mg (64%); mp: 243°C.
1H-NMR (DMSO-d6,
500 MHz) δ (ppm)=2.25 (d, 3H,
4J=0.6 Hz, CH3); 7.18 (tt,
1H,
3J=7.4 Hz,
4J=1.2 Hz C4′H); 7.31 (dm, 2H,
3J=7.6 Hz,
C2′H, C6′H); 7.43 (tm, 2H,
3J=7.9 Hz, C3′H, C5′H); 7.44
(s, 1H,
4J=0.6 Hz, C3H); 7.82 (dd, 1H,
3J=6.3 Hz,
4J=
2.1 Hz, C6H or C7H); 7.83 (dd, 1H,
3J=6.3 Hz,
4J=2.1 Hz,
C6H or C7H); 8.24–8.29 (m, 2H, C5H, C8H), 8.49 (br, 2H,
NH2); 12.25 (s, 1H, NH).
13C-NMR (DMSO-d6, 125 MHz,
303 K): δ (ppm)=18.68 (CH3); 108.08, 109.62 (C4a, C9a);
123.19 (2C, C2′,C 6 ′); 124.43 (C4′); 124.52 (C3); 126.00,
126.13 (C5, C8); 129.82 (2C, C3′,C 5 ′); 132.83, 133.03 (C6,
C7); 133.96, 134.12 (C8a, C10a); 137.55 (C2); 139.40 (C1′);
142.02 (C4); 147.23 (C1); 181.97, 182.04 (C9, C10). The
assignment of the signals was based on one- and two-
dimensional NMR spectra; however, some signals could not
be unambiguously assigned.
EI-MS: m/z (%)=328 (100; [C21H16N2O2]
+·); 311 (8;
[C21H13NO2]
+). High-resolution mass spectrometry (HRMS)
(70 eV, EI): Calcd.: 328.121178. Found 328.1209 ⇒
C21H16N2O2. Anal. Calcd. for C21H16N2O2∙0.25H2O: C,
75.77; H, 5.00; N, 8.42. Found: C, 75.96; H, 4.86; N, 8.45.
1-Amino-2-methyl-4-(3-methylphenylamino)anthraquinone
(24)
The compound was synthesized from 500 mg (1.6 mmol)
of 9 and 2 ml (1.96 g, 18.29 mmol) of 3-methylaniline in
the presence of 350 mg (3.6 mmol) of potassium acetate
and 30 mg (0.16 mmol) of copper(I) acetate. Reaction time:
24 h.
Yield: 384 mg (71%); mp: 255°C.
1H-NMR (DMSO-d6,
500 MHz) δ (ppm)=2.25 (d, 3H,
4J=0.6 Hz, 2-CH3); 2.33
(s, 3H, 3′-CH3); 7.00 (d, 1H,
3J=7.3 Hz, C4′Ho rC 6 ′H);
7.11 (d, 1H,
3J=7.3 Hz, C4′Ho rC 6 ′H); 7.11 (s, 1H, C2′H);
7.31 (t, 1H,
3J=7.9 Hz, C5′H); 7.43 (d, 1H,
4J=0.6 Hz,
C3H); 7.80–7.84 (m, 2H, C6H, C7H); 8.25–8.27 (m, 2H,
C5H, C8H); 12.24 (s, 1H, NH).
13C-NMR (DMSO-d6,
125 MHz, 303 K): δ (ppm)=18.69 (2-CH3); 21.13 (3′-
CH3); 108.05, 109.48 (C4a, C9a); 120.32 (C6′); 123.85
(C2′ or C4′); 124.63 (C3); 125.27 (C2′ or C4′); 126.00,
126.13 (C5, C8); 129.59 (C5′); 132.82, 133.00 (C6, C7);
133.99, 134.12 (C8a, C10a); 137.56 (C2); 139.27, 139.37
(C1′,C 3 ′); 142.22 (C4); 147.21 (C1); 181.86, 182.01 (C9,
C10). EI-MS: m/z (%)=342.2 (100; C22H18N2O2
+·); 325.2
[3; (C22H8N2O2-NH3)
+]. HRMS (70 eV, EI): Calcd.:
342.1368. Found 342.1367 ⇒ C22H18N2O2. Anal. Calcd.
for C22H18N2O2∙0.75H2O: C, 74.24; H, 5.52; N, 7.87.
Found: C, 73.98; H, 5.28; N, 8.16.
1-Amino-2-methyl-4-(4-methylphenylamino)anthraquinone
(25) [49]
The compound was synthesized from 350 mg (1.1 mmol)
of 9 and 2.6 g (24.3 mmol) of 4-methylaniline in the
presence of 245 mg (3.6 mmol) of potassium acetate and
21 mg (0.16 mmol) of copper(I) acetate. Reaction time: 5 h.
Yield: 260 mg (68%).
1H-NMR (DMSO-d6, 500 MHz) δ
(ppm)=2.24 (s, 3H, 2-CH3); 2.32 (s, 3H, 4′-CH3); 7.20
(dm, 2H,
3J=8.5 Hz, C2′H, C6′Ho rC 3 ′H, C5′H); 7.24
(dm, 1H,
3J=8.2 Hz, C2′H, C6′Ho rC 3 ′H, C5′H); 7.37 (s,
1H, C3H); 7.80–7.84 (m, 2H, C6H, C7H); 8.25–8.28 (m,
2H, C5H, C8H); 12.26 (s, 1H, NH).
13C-NMR (DMSO-d6,
125 MHz, 303 K): δ (ppm)=18.69 (2-CH3); 20.65 (3′-
CH3); 107.98, 109.11 (C4a, C9a); 123.70 (2C, C2′,C 6 ′);
124.38 (C3); 125.97, 126.12 (C5, C8); 130.30 (2C, C3′,
C5′); 132.78, 133.91 (C6, C7); 133.99, 134.03, 134.11
(C8a, C10a, C4′); 136.58, 137.64, (C2, C1′); 142.75 (C4);
147.12 (C1); 181.61, 182.94 (C9, C10).
1-Amino-2-methyl-4-(1-naphthylamino)anthraquinone (26)
The compound was synthesized from 400 mg (1.3 mmol)
of 9 and 2.5 g (17 mmol) of 1-aminonaphthalene in the
presence of 280 mg (2.85 mmol) of potassium acetate and
25 mg (0.14 mmol) of copper(I) acetate. Reaction time:
12 h. The product is recrystallized from pyridine.
Yield: 123 mg (20%).
1H-NMR (DMSO-d6, 500 MHz) δ
(ppm)=2.19 (d, 3H,
4J=0.6 Hz, 2-CH3); 7.27 (d, 1H,
4J=
0.6 Hz C3H); 7.55–7.62 (m, 4H, naphthalene); 7.82–7.85
(m, 3H, C6H, C7H, naphthalene); 8.02 (m, 1H, naphtha-
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12.74 (s, 1H, NH).
13C-NMR (DMSO-d6, 125 MHz): δ
(ppm)=18.63 (2-CH3); 108.00, 109.61 (C4a. C9a); 121.35,
121.95 (C2′,C 4 ′); 124.67 (C3); 125.45, 126.10, 126.19,
126.27, 126.82, 127.00, 128.63, 128.81 (C5, C8, C5′,C 6 ′,
C7′,C 8 ′, C4a′, C8a′); 132.84, 133.09, 134.01, 134.22,
134.45, 135.16 (C6, C7, C8a, C10a, C1′,C 3 ′); 137.76 (C2);
143.48 (C4); 147.24 (C1); 181.99, 182.27 (C9, C10). EI-
MS: m/z (%)=378.2 (100; C25H18N2O2
+·). HRMS (70 eV,
EI): Calcd.: 378.1368. Found 378.1365 ⇒ C25H18N2O2.
Synthesis of the sulfonic acid chloride of bromaminic acid
(10) [50]
Bromaminic acid sodium salt (8, 10 g, ca. 25 mmol) was
suspended in 100 ml of phosphorus oxychloride (POCl3)
and phosphorus pentachloride (PCl5, 9 g, 43 mmol) was
added. The reaction mixture was stirred at 95°C under
argon for 6 h. The remaining POCl3 was distilled off under
reduced pressure. Two different methods have been used to
isolate the product: (1) the residue was cooled in an ice bath
and the cold mixture was poured into 200 ml of ice water.
The precipitated solid was filtered off and dried under
vacuum and stored until use; (2) the residue was taken up in
dichloromethane and the resulting solution was washed
three times with 40 ml of ice water each. The organic phase
was dried over anhydrous magnesium sulfate and after
filtration, the solvent was distilled off under vacuum. The
residue obtained was dried and used in the next step
without further purification. Yield: 90–96% (raw product);
mp approximately 190°C (decomposition).
1-Amino-4-bromoanthraquinone-2-sulfonic acid methyl
ester (27)
The sulfonic acid chloride 10 (250 mg, 0.6 mmol) was
suspended in 50 ml of methanol, and sodium methoxide
(approximately 500 mg) was added. The reaction mixture
was stirred under an argon atmosphere for 16 h at RT and
subsequently evaporated to dryness. The residue was
suspended in a mixture of cyclohexane and ethyl acetate
(37:3), silica gel (5 g) was added, and the solvent was
removed by rotary evaporation. The material absorbed on
silica gel was put onto a silica gel column and the product
was purified by column chromatography using cyclohex-
ane:ethyl acetate (37:3) as eluent.
Yield: 143 mg (58%);
1H-NMR (DMSO-d6, 500 MHz,
303 K): δ (ppm)=3.97 (s, 3H, OCH3); 7.52 (br, 1H, NH2);
7.83 (td, 1H,
3J=7.4 Hz,
4J=1.6 Hz, C6H or C7H); 7.87
(td, 1H,
3J=7.4 Hz,
4J=1.7 Hz, C6H or C7H); 8.04 (s, 1H,
C3H); 8.09 (dd, 1H,
3J=7.6 Hz,
4J=1.3 Hz, C5H or C8H);
8.16 (dd, 1H,
3J=7.6 Hz,
4J=1.3 Hz, C5H or C8H); 9.56
(br, 1H, NH2).
13C-NMR (DMSO-d6, 125 MHz, 303 K): δ
(ppm)=62.24 (OCH3); 106.21, 114.79 (C4a, C9a); 126.17,
126.46 (C5, C8); 131.40 (C4); 133.10, 133.68, 133.76,
134.31 (C6, C7, C8a, C10a); 138.63, 138.93 (C2, C3);
148.4 (C1); 182.16, 183.70 (C9, C10).
General procedure for the synthesis
of 1-amino-4-bromoanthraquinone-2-sulfonic
acid nitrophenyl esters
The sulfonic acid chloride 10 (285 mg, 0.7 mmol) was
suspended in 33 ml of freshly distilled dichloromethane and
completely dissolved by stirring it under an argon atmo-
sphere for 30 min. Then a solution of 430 mg (3.1 mmol) of
the appropriate nitrophenol and 4 ml of triethylamine in
8 ml of dichloromethane were added (producing white
fumes). The reaction mixture was stirred until the starting
compound 10 had completely disappeared (TLC control).
The solvent was evaporated and the residue was dissolved
in 10 ml of a mixture of dichloromethane and cyclohexane
(7:2). Subsequent column chromatography on silica gel
using the same solvent mixture gave the pure products.
1-Amino-4-bromoanthraquinone-2-sulfonic acid
2-nitrophenyl ester (28)
Yield: 96 mg (27%); mp 213 – 214°C.
1H-NMR (DMSO-
d6, 303 K, 500 MHz): δ (ppm)=7.32 (dd, 1H,
3J=8.3 Hz,
4J=1.2 Hz, C6′H); 7.63 (ddd, 1H,
3J=8.2 Hz,
3J=7.6 Hz,
4J=1.3 Hz, C5′H); 7.74 (ddd,
3J=8.2 Hz,
3J=7.6 Hz,
4J=
1.6 Hz, C4′H); 7.89 (s, 1H, C3H); 7.91 (td, 1H,
3J=7.3 Hz,
4J=1.7 Hz, C6H or C7H); 7.94 (td, 1H,
3J=7.4 Hz,
4J=
1.8 Hz, C6H or C7H); 8.10 (ddm, 1H,
3J=7.1 Hz,
4J=
1.8 Hz, C5H or C8H); 8.14 (dd, 1H,
3J=8.0 Hz,
4J=1.7 Hz,
C3′H); 8.20 (ddm, 1H,
3J=7.1 Hz,
4J=1.8 Hz, C5H or
C8H).
13C-NMR (DMSO-d6, 125 MHz, 303 K): δ (ppm)=
104.08 (C9a); 118.13 (C4a); 120.62 (C4); 124.87 (C3′ or
C6′); 126.48, 126.58 (C5, C8); 126.60 (C3′ or C6′); 129.44
(C4′); 132.85, 133.62, 134.54, 134.84 (C6, C7, C8a, C10a);
135.65 (C5′); 137.62 (C2); 139.95 (C2′); 142.23 (C3);
142.90 (C1′); 148.21 (C1); 182.15, 184.42 (C9 und C10).
EI-MS: m/z (%)=502.0 + 504.0 (ratio 1:1; 100;
[C20H11BrN2O7S]
+·); 380.9+382.9 (ratio 1:1; 31;
[C14H8BrNO5S]
+·); 300.0+301.9 (ratio 1:1; 84;
[C14H7BrNO2]
+); 221.1 (41; [C14H7NO2]
+·). HRMS
(70 eV, EI): Calcd.: 501.9470. Found: 501.9471 ⇒
C20H11BrN2O7S .A n a l .C a l c d .f o rC 20H11BrN2O7S: C,
47.73; H, 2.20; N, 5.57. Found: C, 47.81; H, 2.26; N, 5.52
1-Amino-4-bromoanthraquinone-2-sulfonic acid
3-nitrophenyl ester (29)
Yield: 215 mg (61%); mp 189°C.
1H-NMR (DMSO-d6, 303
K, 500 MHz): δ (ppm)=7.65 (ddd, 1H,
3J=8.2 Hz,
4J=
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5J=1.1 Hz, C6′H); 7.71 (t, 1H,
3J=8.3 Hz, C5′H);
7.89 (td, 1H,
3J=7.3 Hz,
4J=1.7 Hz, C6H or C7H); 7.92 (td,
1H,
3J=7.4 Hz,
4J=1.7 Hz, C6H or C7H); 8.01 (s, 1H,
C3H); 8.07 (ddm, 1H,
3J=7.0 Hz,
4J=2.0 Hz, C5H or C8H);
8.10 (t,
4J=2.4 Hz, C2′H); 8.16 (ddm, 1H,
3J=7.6 Hz,
4J=
1.6 Hz, C5H or C8H); 8.22 (ddd, 1H,
3J=8.2 Hz,
4J=2.1 Hz,
5J=1.1 Hz, C4′H).
13C-NMR (DMSO-d6, 125 MHz, 303 K):
δ (ppm)=104.28 (C9a); 117.78 (C2′); 117.88 (C4a); 120.72
(C4); 123.15 (C4′); 126.44, 126.57 (C5, C8); 128.83 (C6′);
131.94 (C5′); 132.83, 133.21, 134.50, 134.78 (C6, C7, C8a,
C10a); 137.44 (C2); 142.54 (C3); 148.11 (C1); 148.32,
148.67 (C1′,C 3 ′); 182.03, 184.40 (C9, C10). EI-MS: m/z
(%)=502.0+504.0 (ratio 1:1; 46; [C20H11BrN2O7S]
+·); 424
(84; [C20H11N2O7S]
+·); 300.0+301.9 (ratio 1:1; 45;
[C14H7BrNO2]
+); 286 (49; [C14H8NO4S]
+); 238.0 (61;
[C14H8NO3]
+); 222.0 (100; [C14H7NO2]
+·). HRMS (70 eV,
EI): Calcd.: 501.9470. Found: 501.9469 ⇒ C20H11BrN2O7S.
Anal. Calcd. for C20H11BrN2O7S: C, 47.73; H, 2.20; N,
5.57. Found: C, 50.98; H, 2.29; N, 5.88.
1-Amino-4-bromoanthraquinone-2-sulfonic acid
4-nitrophenyl ester (30)
Yield: 266 mg (76%); mp 196°C.
1H-NMR (DMSO-d6, 303
K, 500 MHz): δ (ppm)=7.49 (dm, 2H,
3J=9.2 Hz, C2′H,
C6′H); 7.89 (td, 1H,
3J=7.4 Hz,
4J=1.6 Hz, C6H or C7H);
7.92 (td, 1H,
3J=7.4 Hz,
4J=1.8 Hz, C6H or C7H); 7.98 (s,
1H, C3H); 8.08 (ddm, 1H,
3J=7.4 Hz,
4J=1.6 Hz, C5H or
C8H); 8.17 (ddm, 1H,
3J=7.4 Hz,
4J=1.3 Hz, C5H or
C8H); 8.26 (dm, 2H,
3J=9.2 Hz, C3′H, C5′H).
13C-NMR
(DMSO-d6, 125 MHz, 303 K): δ (ppm)=104.27 (C9a);
117.96 (C4a); 120.81 (C4); 123.54 (2C, C2′,C 6 ′); 126.19
(2C, C3′,C 5 ′); 126.45, 126.58 (C5, C8); 132.85, 133.23,
134.51, 134.79 (C6, C7, C8a, C10a); 137.47 (C2); 142.42
(C3); 146.61 (C4′); 148.03 (C1); 152.65 (C1′); 182.06,
184.44 (C9 und C10). EI-MS: m/z (%)=502.0+504.0 (ratio
1:1; 30; [C20H11BrN2O7S]
+·); 424 (84; [C20H11N2O7S]
+·);
300.0+301.9 (ratio 1:1; 18; [C14H7BrNO2]
+); 286 (52;
[C14H8NO4S]
+); 238.0 (61; [C14H8NO3]
+); 222.0 (100;
[C14H7NO2]
+·). HRMS (70 eV, EI): Calcd.: 501.9470.
Found: 501.9472 ⇒ C20H11BrN2O7S. Anal. Calcd. for
C20H11BrN2O7S: C, 47.73; H, 2.20; N, 5.57. Found: C,
47.55; H, 2.20; N, 5.52.
General procedure for the synthesis of bromaminic acid
amides (sulfonamides 31–33)
The sulfonic acid chloride 10 was put into a round-bottom
flask flushed with argon and freshly dried and distilled
dichloromethane or acetone, respectively, was added. The
appropriate amine dissolved in a mixture of triethylamine
and dichloromethane was added to the suspension resulting
in the evolvement of white fumes. The reaction mixture was
stirred at RT under an argon atmosphere until starting
compound 10 had completely disappeared [TLC monitoring
on silica gel using cyclohexane:ethyl acetate (17:3) as an
eluent]. Then the solvent was distilled off under reduced
pressure and the residue was dissolved in a mixture of
dichloromethane:cyclohexane:ethyl acetate (40:51:9 or
10:17:3, respectively) or in dichloromethane:cyclohexane
(7:3), respectively, and purified by column chromatography
on silica gel using the same solvent mixture.
1-Amino-4-bromoanthraquinone-2-sulfonic acid phenyl
amide (31) [49]
The compound was prepared from 0.5 g (1.25 mmol) of 10
in 30 ml of dichloromethane and 1.5 ml (1.53 g, 16.5 mmol)
of freshly distilled aniline in 10 ml of dichloromethane.
Reaction time: 16 h at RT; purification by column
chromatography with dichloromethane:cyclohexane:ethyl
acetate (10:17:3) as eluent. Upon evaporation of the
product-containing fractions an orange-red colored product
precipitated, which was collected by filtration and dried.
Yield: 200 mg (18%); mp 214°C (lit. mp 220°C [48]).
1H-NMR (DMSO-d6, 500 MHz, 303 K): δ (ppm)=7.08 (tt,
3J=7.4 Hz, C4′H); 7.11 (m, 2H, C2′H, C6′H); 7.28 (m, 2H,
C3′H, C5′H); 7.81 (td, 1H,
3J=7.3 Hz,
4J=1.7 Hz, C6H or
C7H); 7.84 (td, 1H,
3J=7.4 Hz,
4J=1.7 Hz, C6H or C7H);
8.00 (dd, 1H,
3J=7.1 Hz,
4J=1.8 Hz, C5H or C8H); 8.08 (s,
1H, C3H); 8.09 (dd, 1H,
3J=7.6 Hz,
4J=1.6 Hz, C5H or
C8H); 10.81 (s, 1H, NH).
13C-NMR (DMSO-d6, 125 MHz,
303 K): δ (ppm)=104.67 (C9a); 116.82 (C4a); 120.68 (2C,
C2′,C 6 ′); 125.13 (C4′); 126.26, 126.44 (C5, C8); 126.98
(C4); 129.65 (2C, C3′,C 5 ′); 132.86, 133.30 (C8a, C10a);
134.18, 134.50, 135.33 (C3, C6, C7); 136.51 (C1′); 141.88
(C2); 147.50 (C1); 181.95, 184.28 (C9, C10).
1-Amino-4-bromoanthraquinone-2-sulfonic acid
benzylamide (32)
The compound was prepared from 0.5 g (1.25 mmol) of 10
in 20 ml of dichloromethane, and 0.3 ml (0.29 g,
2.75 mmol) of benzylamine and 0.3 ml of triethylamine in
30 ml of dichloromethane. Reaction time: 16 h at RT;
purification by column chromatography with dichloro-
methane:cyclohexane:ethyl acetate (40:51:9) as eluent.
Yield: 215 mg (37%); mp 189°C.
1H-NMR (DMSO-d6,
303 K, 500 MHz): δ (ppm)=4.12 (s, 2H, CH2); 7.02 (t,
3J=
7.2 Hz, C4′H); 7.14 (t, 2H,
3J=7.7 Hz C3′H, C5′H); 7.18
(d, 2H,
3J=6.8 Hz C2′H, C6′H); 7.87 (td, 1H,
3J=7.2 Hz,
4J=1.4 Hz, C6H or C7H); 7.90 (td, 1H,
3J=7.4 Hz,
4J=
1.7 Hz, C6H or C7H); 8.02 (s, 1H, C3H); 8.07 (dd, 1H,
3J=
7.4 Hz,
4J=1.8 Hz, C5H or C8H); 8.14 (dd, 1H,
3J=7.5 Hz,
4J=1.4 Hz, C5H or C8H); 8.81 (s, 1H, NH).
13C-NMR
(DMSO-d6,1 2 5M H z ,3 0 3K ) :δ (ppm)=46.06 (CH2); 105.19
102 Purinergic Signalling (2009) 5:91–106(C9a); 116.41 (C4a); 126.30, 126.51 (C5, C8); 127.23 (C4′);
127.72, 128.18 (C2′,C 6 ′,C 3 ′,C 5 ′); 128.96 (C4); 132.83,
133.37 (C8a, C10a); 134.22, 134.62, 134.63 (C3, C6, C7);
136.69 (C1′); 141.51 (C2); 147.39 (C1); 182.07, 184.08 (C9,
C10). EI-MS: m/z (%)=471.9+469.9 (ratio 1:1; 8;
[C21H15BrN2O4S]
+·); 392.0 (5; [C21H15 N2O4S]
+·); 300.9
+303 (ratio 1:1; 27; [C14H7BrNO2]
+); 223.1 (29;
[C14H7NO2]
+·); 106.1 (100; [C7H8N]
+). HRMS (70 eV, EI):
Calcd.: 469.993. Found: 469.992 ⇒ C21H15BrN2O4S. Anal.
Calcd. for C21H15BrN2O4S∙1.5 C6H12: C, 60.30; H, 5.57; N,
4.69. Found: C, 60.17; H, 5.21; N, 4.88.
1-Amino-4-bromoanthraquinone-2-sulfonic acid
phenethylamide (33)
The compound was prepared from 0.5 g (1.25 mmol) of 10
in 10 ml of dichloromethane, and 0.3 ml (0.29 g, 2.4 mmol)
of 2-phenethylamine and 0.3 ml of triethylamine in 30 ml
of dichloromethane. Reaction time: 16 h at RT; purification
by column chromatography with dichloromethane:cyclo-
hexane:ethyl acetate (40:51:9) as eluent.
Yield: 296 mg (48%); mp 176°C.
1H-NMR (DMSO-d6,
303 K, 500 MHz): δ (ppm)=2.68 (t, 2H,
3J=7.1 Hz, ArCH2);
3.15 (t, 2H,
3J=7.1 Hz, NHCH2); 7.00 (tt,
3J=6.8 Hz,
4J=
1.9 Hz, C4′H); 7.10–7.16 (m, 4H, C2′H, C3′H, C5′H, C6′H);
7.87 (td, 1H,
3J=7.2 Hz,
4J=1.4 Hz, C6H or C7H); 7.90 (td,
1H,
3J=7.3 Hz,
4J=1.7 Hz, C6H or C7H); 8.08 (ddd, 1H,
3J=7.3 Hz,
4J=1.7 Hz,
5J=0.4 Hz, C5H or C8H); 8.09 (s,
1H, C3H); 8.16 (ddd, 1H,
3J=7.3Hz,
4J=1.6 Hz,
5J=0.3 Hz,
C5H or C8H); 8.33 (s, 1H, NH).
13C-NMR (DMSO-d6,
125 MHz, 303 K): δ (ppm)=35.29 (ArCH2); 43.86
(NHCH2); 105.09 (C9a); 116.67 (C4a); 126.23, 126.31,
126.51 (C5, C8, C4′); 128.23 (2C, C2′,C 6 ′ or C3′,C 5 ′);
128.69 (C4); 128.76 (2C, C2′,C 6 ′ or C3′,C 5 ′); 132.90,
133.45 (C8a, C10a); 134.21, 134.60, 134.78 (C3, C6, C7);
138.49 (C1′); 141.24 (C2); 147.45 (C1); 182.15, 184.22 (C9,
C10). EI-MS: m/z (%)=484.0+486.0 (ratio 1:1; 21;
[C22H17BrN2O4S]
+·); 392.9+394.9 (ratio 1:1; 35;
[C15H10BrN2O4S]
+); 380+381.9 (ratio 1:1; 68;
[C14H8BrN2O4S]
+·); 300.0+302.0 (ratio 1:1; 100;
[C14H7BrNO2]
+); 221.1 (40; [C14H7NO2]
+·); 120.2 (27;
[C7H8N]
+). HRMS (70 eV, EI): Calcd.: 484.00924. Found:
484.0095 ⇒ C22H17BrN2O4S. Anal. Calcd. for
C22H17BrN2O4S∙0.5H2O: C, 53.45; H, 3.67; N, 5.67. Found:
C, 53.50; H, 3.74; N, 5.56.
Bis-(1-amino-4-bromoanthraquinone-2-sulfonic acid)
4-ethoxyphenylamide (34)
The compound was prepared from 1.0 g (2.5 mmol) of 10
in 80 ml of dichloromethane, and 1.0 ml (1.05 g, 7.7 mmol)
of 4-ethoxyaniline and 3 ml of triethylamine in 10 ml of
dichloromethane. Reaction time: 16 h at RT; purification by
column chromatography with dichloromethane:cyclohex-
ane (7:3) as eluent. Upon concentrating the product-
containing fractions under reduced pressure the product
precipitated and was filtered off.
Yield: 180 mg (17%); mp 262°C.
1H-NMR (DMSO-d6:
CDCl3 (approx. 3:1)), 500 MHz, 303 K): δ (ppm)=1.34 (t,
3H,
3J=7.0 Hz, CH3); 4.07 (d, 2H,
3J=7.0 Hz, OCH2); 6.93
(dm, 2H,
3J=8.9 Hz, C2′H, C6′Ho rC 3 ′H, C5′H); 7.19
(dm, 2H,
3J=8.9 Hz, C2′H, C6′Ho rC 3 ′H, C5′H); 7.84 (td,
2H,
3J=6.4 Hz,
4J=2.1 Hz, C6H, C6″H or C7H, C7″H);
7.86 (td, 2H,
3J=6.4 Hz,
4J=2.1 Hz, C6H, C6″H or C7H,
C7″H); 8.01 (s, 2H, C3H, C3″H); 8.04 - 8.08 (m, 2H, C5H,
C5″H or C8H, C8″H); 8.09–8.13 (m, 2H, C5H, C5″Ho r
C8H, C8″H); 8.25 (br, 4H, 1-NH2,1 ″-NH2).
13C-NMR
(DMSO-d6: CDCl3 (ca. 3:1)), 125 MHz, 303 K): δ (ppm)=
14.04 (CH3); 63.54 (OCH2); 104.23 (2C, C9a, C9a″);
115.42 (2C, C3′,C 5 ′); 117.63 (2C, C4a, C4a″); 123.15
(C1′); 124.00 (2C, C4, C4″); 126.03, 126.20 (2C each, C5,
C5″, C8, C8″); 132.48 (C8a, C8a″ or C10a, C10a″); 132.76
(2C, C2′,C 6 ′); 132.85 (C8a, C8a″ or C10a, C10a″); 133.87,
134.10 (2C each, C6, C6″, C7, C7″); 136.74 (2C, C2, C2″);
143.03 (2C, C3, C3″); 147.82 (2C, C1, C1″); 160.46 (C4′);
181.26, 183.71 (2C each, C9, C9″, C10, C10″). EI-MS:
m/z (%)=867.0+865+863 (ratio 1:2: 1; 11;
[C36H23Br2N3O9S]
+·); 500+502.0 (ratio 1:1; 34;
[C22H17BrN2O5S]
+·); 301.0+303 (ratio 1:1; 25;
[C14H8BrNO2]
+); 136.1 (100; [C8H10NO]
+); 108.1 (69;
[C6H6NO]
+). IR (KBr): ν [cm
-1]=3459, 3420 (NH2); 1669
(C=O); 1587 (Ar); 1499 (Ar); 1390, 1366 (SO2NR2); 1254
(C-O); 1160 (SO2NR2); 889 (Ar); 745, 724 (o-subst. Ar).
Bis-(1-amino-4-bromoanthraquinone-2-sulfonic acid)
2-methoxyphenylamide (35)
The compound was prepared from 1.0 g (2.5 mmol) of 10
in 80 ml of dichloromethane, and 1.0 ml (1.092 g,
8.867 mmol) of 2-methoxyaniline and 3 ml of triethylamine
in 10 ml of dichloromethane. Reaction time: 16 h at RT;
purification by column chromatography with dichloro-
methane:cyclohexane (7:3) as eluent.
Yield: 180 mg (14%); mp 271°C.
1H-NMR (DMSO-d6,
500 MHz, 303 K): δ (ppm)=3.60 (s, 3H, CH3); 7.13 (dd,
1H,
3J=8.4 Hz,
4J=1.3 Hz, C3′Ho rC 6 ′H); 7.13 (ddd, 1H,
3J=8.0 Hz,
3J=7.6 Hz,
4J=0.7 Hz, C3′Ho rC 4 ′H); 7.47
(dd, 1H,
3J=8.2 Hz,
4J=1.6 Hz, C3′Ho rC 6 ′H); 7.57 (ddd,
1H,
3J=8.3 Hz,
3J=7.5 Hz,
4J=1.7 Hz, C3′Ho rC 4 ′H);
7.85 (td, 2H,
3J=7.2 Hz,
4J=1.7 Hz, C6H, C6″H or C7H,
C7″H); 7.88 (td, 2H,
3J=7.2 Hz,
4J=1.8 Hz, C6H, C6″Ho r
C7H, C7″H); 8.01 (ddm, 2H,
3J=6.8 Hz,
4J=2.1 Hz, C5H,
C5″H or C8H, C8″H); 8.08 (ddm, 2H,
3J=6.4 Hz,
4J=
2.5 Hz, C5H, C5″H or C8H, C8″H); 8.08 (s, 2H, C3H, C3″
H); 8.35 (br, 4H, 1-NH2,1 ″-NH2).
13C-NMR (DMSO-d6,
125 MHz, 303 K): δ (ppm)=55.53 (OCH3); 103.84 (2C,
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121.15 (C1′,C 5 ′); 124.15 (2C, C4, C4″); 126.05, 126.20
(2C each, C5, C5″, C8, C8″); 132.45, 132.86, 132.99,
133.19 (C8a, C8a″, C10a, C10a″,C 4 ′,C 6 ′); 134.08, 134.35
(2C each, C6, C6″, C7, C7″); 136.75 (2C, C2, C2″); 143.18
(2C, C3, C3″); 148.13 (2C, C1, C1″); 157.11 (C4′); 181.34,
183.66 (2C each, C9, C9″, C10, C10″). EI-MS: m/z (%)=
848.9+850.9+853 (ratio 1:2: 1; 27; [C35H21Br2N3O9S]
+·);
486 + 488.0 (ratio 1:1; 80; [C21H15BrN2O5S]
+·); 301.0+303
(ratio 1:1; 34; [C14H8BrNO2]
+); 122.1 (100; [C7H8NO]
+).
IR (KBr): ν [cm
-1]=3424 (NH2); 2845 (OCH3); 1675 (C=
O); 1594 (Ar); 1366 (SO2NR2); 1257 (CO); 11.78
(SO2NR2); 891 (Ar); 724 (o-subst. Ar).
NTPDase inhibition assays
Enzyme preparations
The preparation of recombinant rat NTPDase1–3w a s
performed essentially as described by Iqbal et al. [27]. In
brief, Chinese hamster ovary (CHO) cells were transfected
by electroporation with plasmid DNA-containing rat
NTPDase1 (GenBank Accession number U81295) [51]a n d
NTPDase2 (Y11835) [51] and NTPDase3 (AJ437217) [52],
all cloned into the pcDNA3 plasmid. Transfection with the
empty plasmid pcDNA3 served as a control. Membrane
fractions were prepared in the presence of protease inhibitors
from transiently transfected CHO cells 48 h after electro-
poration. The final pellet fraction was resuspended in 50%
(v/v) glycerol containing 2 mM iodoacetamide, 20 mM
HEPES (pH 7.4) and stored at -20°C. The membrane prepara-
tions contained 4–6 μgo fp r o t e i n / μl.
Enzyme assay
Stock solutions (10 mM or 1 mM) of test compounds were
prepared in water or water containing 10% DMSO for the
more lipophilic compounds, respectively, and dilutions
were made in assay buffer (140 mM NaCl, 5 mM KCl,
1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, pH 7.4). The
reaction mixture for NTPDase inhibition assays contained
ATP (final concentration 400 μM) dissolved in assay buffer
and test compound (10 μl, different concentrations). The
reaction was started by the addition of 10 μl of enzyme-
containing membrane preparation to obtain a final volume
of 100 μl. Control experiments were performed using
membrane preparations of cells transfected with the empty
plasmid (pcDNA3). The reaction was carried out at 37°C
for 10 min and stopped by heating at 99°C for 3 min. Then
50 μl were transferred to a CE vial and mixed with an UMP
solution (final concentration 10 μM, internal standard) in
450 μl of water. The resulting solution was subjected to CE
analysis using a P/ACE MDQ CE system (Beckman
Instruments, Fullerton, CA, USA) equipped with a UV
detection system coupled with a diode array detector. The
capillary temperature was kept constant at 25°C. The
temperature of the sample storing unit was adjusted to
25°C. The electrophoretic separations were carried out
using an eCAP polyacrylamide-coated fused-silica capillary
[30 cm (20 cm effective length)×50 μm internal diameter×
360 μm outer diameter, obtained from CS-Chromatogra-
phie (Langerwehe, Germany)]. The separations were
performed with phosphate buffer 50 mM, pH 6.5 using an
applied current of -60 μA and a data acquisition rate of
8 Hz. Analytes were detected using direct UVabsorbance at
210 nm. The capillary was conditioned by rinsing with
water for 2 min and subsequently with phosphate buffer for
1 min. Sample injections were made at the cathodic side of
the capillary. Data collection and peak area analysis were
performed by the P/ACE MDQ software 32 KARAT.
Inhibition curves were analyzed by Prism 3.0 (GraphPad,
San Diego, CA, USA).
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